Atopic Dermatitis Plaque Psoriasis
A child and a woman in the bathroom A child and a woman in the bathroom
Not actual patients/caregiver.

Safe and well tolerated for patients with atopic dermatitis down to
2 years of age2

Not actual patients/caregiver.

Favorable safety profile

Adverse reactions occurring in ≥1% of patients during the 8-week pivotal studies, ADORING 1 and ADORING 21,2

Adverse Reaction
VTAMA cream
(N=541)
n (%)
Vehicle
(N=270)
n (%)
Upper respiratory tract infection
66 (12)
15 (6)
Folliculitis
51 (9)
3 (1)
Lower respiratory tract infection
25 (5)
6 (2)
Headache
23 (4)
3 (1)
Asthma
12 (2)
1 (0)
Vomiting
10 (2)
2 (1)
Ear infection
10 (2)
1 (0)
Pain in extremity
9 (2)
1 (0)
Abdominal pain
6 (1)
0 (0)
  • Study discontinuation rates lower in VTAMA cream–treated group vs vehicle-treated group2
    • ADORING 1: 1.9% VTAMA cream vs 3.6% vehicle
    • ADORING 2: 1.5% VTAMA cream vs 3.0% vehicle
A child painting her nails
Not an actual patient.

Safe and well tolerated,
even on sensitive skin areas

There are no label restrictions on topical use. No-to-minimal irritation, even on affected sensitive skin areas such as the face, neck, and skin folds based on local tolerability scores.*‡1,6

Safety

The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis treated with VTAMA cream were upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

Icon of a warning symbol within a circle with a line through it

No Boxed Warning or contraindications.1

Icon of two pill bottles within a circle with a line through it

No drug-drug interactions.1

Icon of a negative symbol within a circle with a line through it

No label restrictions on topical use and can be applied to all affected skin areas.*1

Icon of a vial within a circle with a line through it

No-to-minimal systemic absorption.2

Tolerability
Icon of a fire symbol within a circle with a line through it

No-to-minimal stinging or burning based on local tolerability scores.†6

*Not for oral, ophthalmic, or intravaginal use.

†Patient/caregiver-reported tolerability scores (0-4) assessed the presence and degree of burning/stinging and of itching at the application sites, from (0) none to (1) slight, (2) mild, (3) moderate, or (4) strong/severe.6

‡Investigator-assessed tolerability scores (0–4) were assessed using the LTS which evaluated the presence and overall degree of irritation across application sites (including dryness, erythema, and peeling), from (0) no irritation to (1) mild, (2) moderate, (3) severe, or (4) very severe.

Rapid itch relief

See how VTAMA cream may provide rapid itch relief2-4
Long-term results

VTAMA cream was studied in a 48-week, open-label, long-term extension study5

INDICATION: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

SELECTED SAFETY INFORMATION

Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

INDICATION: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

SELECTED SAFETY INFORMATION

Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

Before prescribing VTAMA cream, please read the Prescribing Information.

Back to top